Shahnaz Kheirandish

Shahnaz Kheirandish

Auto-generated profile, based on publicly available information

Shahnaz Kheirandish

Department of Clinical Biochemistry, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016
Verified
Journal Article
Closed access
KKKhadijeh Mirzaee Khoram-Abadi
Khadijeh Mirzaee Khoram-Abadi
MFMohammad Forat-Yazdi
Mohammad Forat-Yazdi
SKShahnaz Kheirandish
Shahnaz Kheirandish
NSNasim Saeidi
Nasim Saeidi
ZZZeinab Zarezade
Zeinab Zarezade
HNHossein Neamatzadeh
Hossein Neamatzadeh

27 September 2016 in International Journal of Basic Science in Medicine
Verified
Journal Article
Open access
MAMohammad Hossein Bakhshi Aliabad
Mohammad Hossein Bakhshi Aliabad
SKShahnaz Kheirandish
Shahnaz Kheirandish
ZZZeynab Zarezadeh
Zeynab Zarezadeh
NSNasim Saeidi
Nasim Saeidi
HKHamid Kabiri
Hamid Kabiri
MMMahta Mazaheri
Mahta Mazaheri
Micro-RNAs (miRNAs) are small molecules that modulate the translation of target mRNA through binding to these molecules. In cancer, the expression of oncogenes and suppressors are increased and decreased, respectively. MiRNAs are one of the causing factors in the formation of cancer. To collect data, research articles in PubMed and Google Scholar were searched under keywords including breast cancer and micro-RNA. The data obtained from articles published in prestigious journals showed that some miRNAs are involved in the suppression and some in the induction of cancer cell growth in breast cancer tissue. Some of them are also involved in the aggression and metastasis. According to the obtained results, it seems that assessing miRNAs in breast cancer tissue can be considered as a potential candidate for prognosis and may be used in pre-diagnosis of the disease in near future.

1 October 2023 in Current Molecular Medicine
Verified
Journal Article
Closed access
PDF file
MHMohsen Hemmati-Dinarvand
Mohsen Hemmati-Dinarvand
HMHossein Mokhtari
Hossein Mokhtari
Iraj AlipourfardIraj Alipourfard
Iraj Alipourfard
EAElham Beyrami Aghbash
Elham Beyrami Aghbash
SKShahnaz Kheirandish
Shahnaz Kheirandish
ASAtefeh Seghatoleslam
Atefeh Seghatoleslam
Object(s): Shortly after cancer is diagnosed, a phenomenon develops in cancer cells called multidrug resistance (MDR), in which cell sensitivity against anti-cancer drugs is significantly reduced. The present investigation aimed to assess the effects of nitazoxanide (NTZ), a safe drug, on LS174T/OXP-resistant cells. Methods: In the current in vitro research, the effects of NTZ and oxaliplatin (OXP) on the viability of LS174T and LS174T/OXP cell lines were evaluated through MTT assay. Then, the changes in expression levels of MDR1, MRP1, BCRP, and LRP genes and proteins were measured by RT-qPCR and western blotting methods, respectively. Lastly, the apoptosis status was assessed by annexin V–FITC/PI staining flow cytometry assay. Results: The IC50 values for cells resistant or sensitive to OXP were revealed (11567 nM vs. 1745 nM; p <0.05 for 24 h incubation, and 5161 nM vs. 882.2 nM; p <0.05 for 48 h incubation). Moreover, NTZ plus OXP led to a leftward shift in the cytotoxicity curve (2004 nM; p = 0.007). This co-treatment significantly decreased the expression of all genes and proteins (p <0.05). Finally, the combination of NTZ and OXP induced a significant increase in apoptosis (p <0.001). Conclusion: The data showed that NTZ treatment could increase the sensitivity of LS174T/OXP cell line to the OXP cytotoxic effects. Thus, NTZ may be efficient in reducing drug resistance in clinics by means of the negative regulation of ATP-binding cassette (ABC) transporters. However, further studies are necessary to explain the exact mechanisms of NTZ.